HER2検査市場：市場規模（セグメント別）、シェア、規制、償還、予測（～2033年）

乳がんは女性で最も頻度の高いがんであり、現在、世界中で女性のがん関連死亡の主な原因となっています。2018年には約1,800万件の乳がん症例が新たに報告され、新たに診断された症例は約210万件で、女性のがん症例のほぼ4人に1人を占めています。

ヒト上皮成長因子受容体2（HER2）は、上皮成長因子受容体（EGFR）ファミリーに属する膜貫通型チロシンキナーゼ受容体です。このタンパク質は、17番染色体の長腕（17q12-21.32）に位置するHER2（ERBB2）遺伝子によってコードされています。HER2の不適切な活性化は、乳がん、胃がん、卵巣がん、結腸直腸がん、膵がん、子宮内膜がんを含むいくつかの悪性腫瘍の発生と関連しています。HER2の状態を正確に評価することは、抗HER2標的療法が最も有効であろう患者を同定するために極めて重要です。

乳がんでは、HER2遺伝子の増幅は患者の18％から20％にみられます。一方、胃がん患者のHER2陽性率は、組織学的サブタイプや部位によって10％から30％と幅があります。

HER2検査モデルには、HER2免疫組織化学（IHC）検査、HER2 In Situハイブリダイゼーション（ISH）検査、HER2比較ゲノムハイブリダイゼーション（aCGH）検査が含まれます。

当レポートは、世界のHER2検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているHER2検査と競合情勢

• 主要な業界動向の洞察
• HER2検査のセグメント別総市場収益と2015年～2033年の市場展望
• セグメント別の手技総数、台数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• HER2検査市場のSWOT分析
• HER2検査市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

List of Tables

Not Applicable

List of Figures

Not Applicable

Abstract

HER2 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on HER2 Tests market for the year 2020 and beyond. Breast cancer is the most frequent cancer in women and is now the leading cause of female cancer-related deaths worldwide. Approximately 18 million new breast cancer cases were reported in 2018, with approximately 2.1 million newly diagnosed cases, accounting for almost 1 in 4 cancer cases among women.

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs). The protein is encoded by the HER2 (ERBB2) gene, which is located on the long arm of chromosome 17 (17q12-21.32). The inappropriate activation of HER2 is associated with the development of several malignancies, including breast, gastric, ovarian, colorectal, pancreatic, and endometrial cancers. An accurate evaluation of HER2 status is crucial for identification of patients who would most likely benefit from targeted anti-HER2 therapies.

In breast cancer, HER2 gene amplification, occurs in 18% to 20% of patients. On the other hand, the reported HER2 positivity in patients with gastric cancer ranges widely from 10% to 30% depending on the histologic subtype and location.

HER2 Tests model includes HER2 Immunohistochemistry (IHC) Tests, HER2 In Situ Hybridization (ISH) Tests and HER2 Comparative Genomic Hybridization (aCGH) Tests

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed HER2 Tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total HER2 tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for HER2 Tests market.
• Competitive dynamics insights and trends provided for HER2 Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Agilent Technologies Inc, Amoy Diagnostics Co Ltd, Biocare Medical LLC, Merck KGaA,F. Hoffmann-La Roche Ltd, Illumina Inc, Danaher Corp, medac GmbH, New England Biolabs Inc, Qiagen NV, Sysmex Corp, Thermo Fisher Scientific Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the HER2 Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on HER2 Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving HER2 Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HER2 Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific HER2 Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable